QGEN Nov 2024 45.000 call
| Previous close | 2.4000 |
| Open | 2.4000 |
| Bid | 1.9000 |
| Ask | 3.7000 |
| Strike | 45.00 |
| Expiry date | 2024-11-15 |
| Day's range | 2.4000 - 2.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.51k |
ZacksQIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
GlobeNewswireQIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced
GlobeNewswireQIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and timeVenlo, the Netherlands, May
